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Abstract
Our aim was to study whether the aberrant amount or function of regulatory T
cells is related to the development of type 1 diabetes (T1D) in children. We also
set out to investigate the balance of different T cell subtype markers during the
T1D autoimmune process. Treg cells were quantified with flow cytometric assay,
and the suppression capacity was analysed with a carboxyfluorescein succinimidyl
ester (CFSE)-based T cell suppression assay in children in various phases of T1D
disease process and in healthy autoantibody-negative control children. The
mRNA expression of different T cell subpopulation markers was analysed with
real-time qPCR method. The proportion and suppression capacity of regulatory
T cells were similar in seroconverted children at an early stage of beta cell
autoimmunity and also in children with T1D when compared to healthy and
autoantibody-negative children. Significant differences were observed in the
mRNA expression of different T cell subpopulation markers in prediabetic
children with multiple (≥2) autoantibodies and in children with newly diagnosed
T1D when compared to the control children. In conclusion, there were no
quantitative or functional differences in regulatory T cells between the case and
control groups in any phase of the autoimmune process. Decreased mRNA
expression levels of T cell subtype markers were observed in children with
multiple islet autoantibodies and in those with newly diagnosed T1D, probably
reflecting an exhaustion of the immune system after the strong immune
activation during the autoimmune process or a generally aberrant immune
response related to the progression of the disease.
Introduction
Type 1 diabetes (T1D) is a severe and chronic autoimmune
disease which originates from the combination of genetic
susceptibilities and environmental factors. Seroconversion
to positivity for beta cell-specific autoantibodies, such as
IAA, GADA, IA-2A and ZnT8A, strongly predicts
progression to overt type 1 diabetes [1]. However, it is
generally accepted that autoreactive CD4+ and CD8+ T
cells mediate the actual destruction of the insulin-
producing beta cells in the pancreatic islets [2].
According to the Th1/Th2 paradigm, Th1 cells are the
most important players in many organ-specific autoim-
mune diseases, while Th2 effector cells are perceived to
have a protective role in autoimmunity [3]. It has become
clear that this Th1/Th2 paradigm is insufficient to explain
all the immunopathology of different autoimmune diseases
such as type 1 diabetes [4]. The third member of effector T
cells is the more recently found Th17 subset which secrete
mainly pro-inflammatory IL-17 cytokine. Th17 cells play a
role in the cell destruction at least in some of the
autoimmune diseases, and it is possible that Th1 and Th17
cells are functioning at different phases of the autoimmune
process [5, 6].
The most important immune regulators are CD4+,
CD25+ Treg cells, which differentiate naturally in thymus
(nTreg) or after induction in peripheral tissues (iTreg) [7].
Treg cells suppress the proliferation and function of
autoreactive Teff cells (self-tolerance) and maintain the
overall balance of the immune system. FOXP3 transcription
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factor is considered as a specific marker and the main
regulator for the differentiation and function of Treg cells [8,
9]. In humans, the mutation in the FOXP3 gene is known to
cause the X-linked syndrome (IPEX) characterized by
immune dysregulation, polyendocrinopathy, enteropathy
and X-linked inheritance [10]. The suppressive mechanisms
of the Treg cells are still quite poorly defined, but it is likely
that different cytokines (TGF-b and IL-10) and cell–cell
contacts play a significant role in the suppression [11].
Multiple mechanisms may lead to the loss of self-
tolerance in autoimmunity [12]. Defects in Treg number
and/or function have been implicated in the development
of different autoimmune diseases such as type 1 diabetes
[13–15]. However, there are also contrasting results [16–
18]. Some studies have shown increased Teff resistance to
Treg suppression, which may lead to the defective
regulation in type 1 diabetes [19, 20]. Homeostatic
cytokines affect markedly the balance between Teffs and
Tregs and are necessary to maintain peripheral self-
tolerance [21, 22].
Most of the previous Treg analyses in type 1 diabetes
have been performed after the clinical diagnosis of T1D.
The aim of this study was to investigate whether there are
differences in regulatory T cells or T cell subpopulation
markers between children with type 1 diabetes-associated
autoimmunity, analysed from the early preclinical phase to
long-lasting type 1 diabetes and healthy controls.
Methods
Subjects. The study population includes children aged 0–
15 years from various stages of type 1 diabetes autoim-
munity, who were divided into four different case groups
(Table 1). The first case group comprises 20 healthy
children who had recently seroconverted to positivity for
one beta cell-specific autoantibody with the mean age of
0.5 years when first positive for islet autoantibodies (range
0.0–1.0 years). The second case group includes 22 children
testing positive for multiple autoantibodies. These two case
groups were recruited from the prospective Type 1
Diabetes Prediction and Prevention (DIPP) study at the
Department of Paediatrics, Oulu University Hospital. The
third case group consists of a total of 30 children with
newly diagnosed type 1 diabetes, time from diagnosis
ranging between 5–17 days at sample collection. The
fourth case group includes 22 patients with long-lasting
type 1 diabetes (mean disease duration 6.9 years, range
2.8–13.1 years). Children in the latter two case groups
were recruited from the Diabetes Clinic at the Department
of Paediatrics, Oulu University Hospital. The control
children selected from the DIPP study for each of the case
groups were age-, sex- and sampling date-matched healthy
and autoantibody-negative children carrying HLA-DQB1
risk-associated genotypes (control groups 1–4). There were
altogether 55 control children. Thirty controls were T
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included in more than one control group. However, the
controls were never used as a duplicate in the same control
group (Table 1).
Quantitation of the regulatory T cells with the flow cytometric
assay. Peripheral blood samples were collected in BD
Vacutainer Cell Preparation Tubes (CPT). Peripheral blood
mononuclear cells (PBMCs) were freshly isolated and frozen
at 70 °C. For the flow cytometry analysis, stored PBMCs
were thawed in +37 °C water bath. Next the cells were
permeabilized and fixed with FOXP3 fix/perm kit (eBio-
sciences) according to the manufacturer’s instructions.
Non-specific interactions between TCR and fluorochromes
were blocked by incubation for 20 min with human IgG.
Finally, the cells were stained with PerCP-CD4, APC-
CD25 (BD Pharmingen, San Diego, CA) and Alexa Fluor
488-FOXP3 (eBiosciences) antibodies and analysed with
BD LSRFortessa. Representative plots of unlabelled and
labelled samples from the FACS analysis and gating
information are presented in Fig. 1A, B.
Suppression assay for regulatory T cells. CD4+ cells were
first enriched from fresh peripheral blood samples collected
in BD Vacutainer Cell Preparation Tubes (CPT). The
enrichment of CD4+ cells was performed <2 h after
venipuncture with Human CD4 + T Cell Enrichment
Cocktail (Stemcell Technologies, Vancouver, BC, Canada)
according to the manufacturer’s instructions. Isolated
CD4+ cells were cultured in RPMI-1640 medium con-
taining 1 mmol/l L-glutamine, 5 mmol/l HEPES, 5%
male human AB serum-inactivated for 20 min at 45 °C
(Lonza) and 1% penicillin/streptomycin overnight at 37 °C
and 5% CO2. On the next day, the cells were suspended in
1xPBS–0.1% human AB serum buffer and stained with
PerCP-CD4, PE-CD127 and APC-CD25 (BD Pharmingen,
San Diego, CA) antibodies. After the labelling, CD4+ cells
were sorted for CD4+CD25+CD127/low T cell (Treg) and
CD4+CD25CD127+ T cell (Teff) fractions with BD
FACSAria II. Sorted Teff cells were labelled with 2 mmol/l
carboxyfluorescein diacetate succinimidyl ester (CFSE) for
7 min at 37 °C and 5% CO2. After the labelling, the Teff
cells were centrifuged and resuspended in the cell culture
medium. CFSE was inactivated by 15-min incubation at
37 °C and 5% CO2. For the suppression assay, Teff cells
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Figure 1 Representative plots and the gating information from the Treg FACS analysis. Lymphocytes were first gated from peripheral blood mononuclear
cells (left). Second, the CD4+ cells were selected (middle). Third, FOXP3+CD25+ cells were visualized and considered as regulatory T cells (gate Q2 on the
right plot). A: An unlabelled sample represents a negative control. B: A sample after labelling the PBMCs with PerCP-CD4, Alexa Fluor 488-FOXP3 and
APC-CD25. The samples were measured with BD LSRFortessa and then analysed with FlowJo cell analysis software. FSC stands for forward scatter and
SSC stands for side scatter in the flow cytometry analysis.
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were cultured in U-bottom 96-well plates as a single
culture and also with Treg cells as a co-culture (Treg:Teff,
1:2 ratio) and stimulated with anti-CD3/CD28 antigen-
coated beads (1:20 ratio). As a control, Teff and Treg cells
were also co-cultured without any stimulating agent. After
6 days, the cultured cells were stained with PE-CD4 (BD
Pharmingen, San Diego, CA) to analyse the proliferation of
CFSE-labelled Teff cells with BD LSRFortessa flow
cytometer. The suppression percentage was calculated with
the following formula: 100[(% proliferation in the
presence of Treg/% proliferation in the absence of
Treg) 9 100] (Fig. 2) [23].
RNA extraction and real-time quantitative PCR (qPCR)
analysis. Peripheral blood samples were collected into
Paxgene RNA Tubes (Qiagen, Valencia, CA) and frozen at
70 °C according to the manufacturer’s instructions. For
analysing mRNA levels, the RNA was first isolated with
the Blood RNA extraction kit (Applied Biosciences) and
then converted to cDNA with the High-Capacity cDNA
Reverse Transcription Kit (Applied Biosystems). Real-time
qPCR was then carried out using the TaqMan Gene
Expression Assay Kit (Applied Biosystems). The house-
keeping gene 18S RNA was used for normalization, and
the real-time qPCR was performed as a multiplex reaction.
The relative mRNA gene expression of T cell markers
(Th1 = T-bet, Th2 = GATA3, Th17 = RORC, Treg=-
FOXP3 and CTLA-4 as a co-stimulatory factor that affects
Treg cell function) was quantitated as a fold change against
the common control sample by using the 2ΔΔCT method
[24]. A sample from the RT-PCR performed without a
reverse transcriptase enzyme was used as a negative control
for detecting possible genomic DNA contaminations.
Beta cell-specific autoantibodies. Autoantibodies against
pancreatic beta cells were analysed from serum samples
with immunofluorescence (islet cell autoantibodies, ICA)
and specific radiobinding assays (IAA, GADA and IA-2A)
as previously described [25].
Statistical analysis. Differences in the mRNA gene
expression levels, relative amount of Treg cells and
percentage of suppression capacity between the case and
control children were analysed with the nonparametric
Mann–Whitney U-test using the SPSS statistical program
(version 22.0). A two-tailed P value <0.05 was considered
statistically significant.
Ethics. Informed consent has been obtained from all
study subjects and/or their guardians, and the studies have
been carried out in accordance with the principles of the
Declaration of Helsinki as revised in 2008.
Results
Flow cytometric analysis of regulatory T cells
We quantitated the relative Treg number by analysing
CD4+CD25+FOXP3+ cells from peripheral blood samples
(Fig. 3). There were no statistically significant differences
in the relative quantity of peripheral Tregs between the
case and control groups at any stages of beta cell
autoimmunity (case–control group 1: 1.52% versus
1.61% P = 0.256, case–control group 2: 1.66% versus
1.86% P = 0.372, case–control group 3: 1.56% versus
1.43% P = 0.980, case–control group 4: 2.14% versus
1.70% P = 0.218).
The T cell suppression assay
The function of the Treg cells was of the same magnitude
between children with beta cell autoimmunity and their
age- and sex-matched autoantibody-negative controls
during preclinical type 1 diabetes (case–control group 1:
59.6% versus 52.7% P = 0.626; case–control group 2:
43.8 versus 50.6 P = 0.340) when autologous Tregs and
Teffs were used in the assay protocol (Fig. 4). Neither
were any significant differences observed when comparing
the children with clinical type 1 diabetes to control
children (case–control group 3: 53.7% versus 46.8%
P = 0.820; case–control group 4: 38.9% versus 44.1%
P = 0.694).
Quantitative real-time qPCR analysis
The balance of the T cell-mediated immune system was
analysed by measuring the transcription factor mRNAs
expressed specifically by different T cell subsets. An
overall decrease in the mRNA expression of several
transcription factors was observed in prediabetic children
positive for multiple islet autoantibodies in comparison
with autoantibody-negative control children (RORC
(Th17): 0.44 versus 0.53 P = 0.163; FOXP3 (Treg):
0.56 versus 0.62 P = 0.151; T-bet (Th1): 0.34 versus 0.63
P < 0.001; GATA3 (Th2): 0.35 versus 0.46 P = 0.003;
CTLA4 (Treg): 0.59 versus 0.68 P = 0.026) (Fig. 5B)
and in children with newly diagnosed type 1 diabetes
(RORC (Th17): 0.36 versus 0.52 P = 0.046; FOXP3
(Treg): 0.47 versus 0.61 P = 0.005; T-bet (Th1): 0.24
versus 0.37 P < 0.001; GATA3 (Th2): 0.30 versus 0.50
P < 0.001; CTLA4 (Treg): 0.59 versus 0.64 P = 0.126)
(Fig. 5C).
There was a similar but non-significant trend towards
decreased expression of the analysed transcription factors
among subjects with long-standing type 1 diabetes
(RORC (Th17): 0.45 versus 0.55 P = 0.141; FOXP3
(Treg): 0.61 versus 0.62 P = 0.606; T-bet (Th1): 0.50
versus 0.54 P = 0.378; GATA3 (Th2): 0.41 versus 0.47
P = 0.076; CTLA4 (Treg): 0.65 versus 0.74 P = 0.660)
(Fig. 5D).
No differences were seen in the early stage of beta cell
autoimmunity when children with recent seroconversion to
positivity for a single autoantibody were compared to
autoantibody-negative controls (RORC (Th17): 0.51 versus
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0.33 P = 0.770; FOXP3 (Treg): 0.64 versus 0.59
P = 0.077; T-bet (Th1): 0.40 versus 0.50 P = 0.872;
GATA3 (Th2):0.50 versus 0.46 P = 0.198; CTLA4
(Treg):0.96 versus 0.68 P = 0.077) (Fig. 5A).
Discussion
A reduced number of regulatory T cells is one of the
potential factors affecting the development of childhood
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Figure 2 Representative plots and the gating
information from the Treg suppression assay.
After 6 days’ stimulation with anti-CD3/
CD28 beads, viable lymphocytes were first
gated (upper left). The second gate was created
for the CD4+ cells (upper right). The third
gate (lower left) represents proliferated Teff
cells and the proliferation % was expressed by
the histogram (lower right). The suppression
% was calculated from stimulated Teff cells
with or without Tregs, as, for example, 100
(51.8/71.5) 9 100% = 27.6% (Fig. 2B and
2C). A: Representative figure from a cell co-
culture (Teff + Treg) with no stimulating
agent. B: Single culture where Teff cells were
stimulated with anti-CD3/CD28 beads
without suppressing Treg cells. C: In co-
culture, Treg and Teff cells were cultured and
stimulated with anti-CD3/CD28 beads in the
same well.
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type 1 diabetes. Previous studies have shown that there are,
however, no alterations in the relative quantity of Treg
cells in adult patients with clinical type 1 diabetes [14, 16,
17]. We wanted to investigate whether the results are
similar also in children (<15 years) with type 1 diabetes
and to study the preclinical phase of type 1 diabetes before
the clinical diagnosis. Our results are in line with previous
studies. There was no difference in the relative quantity of
Treg cells in children with newly diagnosed or long-
standing type 1 diabetes when compared to the non-
diabetic autoantibody-negative control children. Further-
more, we did not observe any changes in the relative
proportion of Tregs in children testing positive for beta
cell-specific autoantibodies.
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Figure 3 Proportion of lymphocytes
expressing CD4+CD25+FOXP3+ (Treg) from
all peripheral blood CD4+ cells in various
phases of type 1 diabetes autoimmunity.
Previously freshly isolated and frozen
peripheral blood mononuclear cells (PBMCs)
were thawed and stained with PerCP-CD4,
Alexa Fluor 488-FOXP3 and APC-CD25
fluorochromes and measured with BD
FACSFortessa. Results were analysed with
FlowJo software. Box and whisker plots
represent the relative number of Treg cells
(%), and every plot includes the median (solid
line), interquartile range (IQR), range and
outliers. The whiskers represent 1.5
interquartile ranges.
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There are conflicting results from studies analysing the
functionality of regulatory T cells in type 1 diabetes [14,
17, 26, 27]. We could not observe any differences in the
suppression capacity of Treg cells between children with
type 1 diabetes autoimmunity and autoantibody-negative
controls. It is noteworthy, however, that the in vitro
suppression assay is very sensitive for changes in the
protocol. Treg sorting and gating methods influence
greatly the composition of the isolated Treg pool and
hence the degree of suppression. Also, the strength and
type of the stimulus used in the assay is critical and may
affect the results remarkably [28, 29].
Decreased gene expression of several transcription
factors specific for various T cell subpopulations was
observed at the mRNA level in children with newly
diagnosed type 1 diabetes as well as during the
preclinical period in children testing positive for mul-
tiple islet autoantibodies when compared to healthy
children. There was a similar but non-significant trend
among subjects with long-lasting type 1 diabetes. No
difference was seen at the early stage of beta cell
autoimmunity when recently seroconverted children
positive for a single autoantibody only were compared
to autoantibody-negative controls.
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Figure 4 Suppression capacity (%) of
autologous Treg cells during the T1D
progression. Subjects from various stages of
T1D autoimmunity (case groups 1, 3, 5 and 7)
were compared with age- and sex-matched
control children who remained autoantibody
negative (control groups 2, 4, 6 and 8). The
suppression capacity was analysed with a
carboxyfluorescein succinimidyl ester (CFSE)-
based T cell suppression assay. After 6 days
in vitro stimulation with CD3/CD28 beads, the
single (Teff) and co-cultured (Teff + Treg)
cells were labelled with PE-CD4. The
suppression capacity of Treg cells was
measured with BD FACSFortessa, and the
percentage of suppression was calculated as
100-(Teff+Treg)/Teff 9 100%. Mean values
for each group are indicated by a horizontal
line.
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Figure 5 Relative mRNA expression levels,
measured from total peripheral blood RNA, of
different T cell subset markers in the various stages
of type 1 diabetes. The relative mRNA expression
analysis for T cell markers (Th1 = T-bet,
Th2 = GATA3, Th17 = RORC, Treg = FOXP3
and CTLA-4) was performed with real-time qPCR
assay and quantitated as a fold change against the
common control by using the 2ΔΔCT method. A:
recently seroconverted children, B: children positive
formultiple autoantibodies, C: childrenwith newly
diagnosedT1D,D:childrenwith long-lastingT1D.
Case groups are represented by black bars, and age-
and sex-matched control children for each group are
shown in white bars.
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Decreased Th1 immune response and low cytokine
secretion have been reported previously in patients with
recently diagnosed type 1 diabetes [30]. Other studies have
also shown a general downregulation of genes involved in
immune response pathways in patients with type 1 diabetes
[31, 32]. Ryde´n et al. have speculated that the reduced
Th1-associated immunity and decreased spontaneous
cytokine secretion could be an effect of exhaustion of the
immune system after the strong immune activation
preceding the diagnosis of T1D. These observed abnor-
malities could be normalized in children with long-
standing T1D when the autoimmune process is coming to
an end and the immune system is partly recovering [33].
Our observed results of a decrease in expression of T cell-
specific transcription factors during the active T1D-
associated autoimmune process can be interpreted to
support this hypothesis. Decrease seen in gene expression
analysis, but not in Treg cell proportion, may reflect post-
transcriptional or translational regulation.
The strength of our study is a very comprehensive study
population from the early stage of the development of beta
cell-specific autoimmunity to long-lasting type 1 diabetes.
Our study cohort consists of population-based cases and
age-, sex- and sampling date-matched controls. All samples
were handled immediately after the sampling by the same
personnel, and there was no shipping of the samples. Treg
cell research is a challenging field due to the plastic and
unstable nature of Treg cells. There are a complex set of
regulatory T cell subtypes, and in certain conditions, Treg
cells may lose their suppressive capacity and switch their
phenotype to Teff cells [27, 28, 34]. Also, the lack of
specific markers for reliable characterization and sorting
regulatory T cells may lead to the inconsistent study
results. Most of the conventional Treg markers are also
expressed in activated effector T cells [8]. The main
limitation in this study is using the peripheral blood T
cells for in vitro assays and analysis. The local milieu in the
pancreatic islets of Langerhans may differ from the systemic
state. It is possible that there are certain inflammatory
cytokines and antigen-presenting cell types which influ-
ence Treg cell function and promote the development of
the autoimmune process. Human post-mortem samples
from the pancreas have revealed that FOXP3+ cells are not
commonly found in inflamed islets [35]. Patients with type
1 diabetes have been observed to have functionally
defective CD4+CD25+ Treg cells in their pancreatic lymph
nodes, but not in peripheral blood [36].
Cytokines play a critical role in Treg differentiation and
survival. Dysregulation of such inflammatory molecules
could lead to the loss of function in Treg cells and
imbalanced equilibrium between regulatory and effector T
cells [8, 21]. Previous studies have shown that impaired
cytokine secretion is related to type 1 diabetes progression
[33, 37, 38]. In future, it would be interesting to analyse
also in our study population whether there are any changes
in cytokine expression in children with T1D autoimmu-
nity.
In conclusion, we demonstrate that there are no
alterations in the proportion or suppression capacity of
Tregs in children with type 1 diabetes autoimmunity in
the preclinical or clinical phase of type 1 diabetes. The gene
expression of several specific transcription factors for
different T cell subtypes was clearly declined in prediabetic
children with multiple islet autoantibodies and also in
children with newly diagnosed type 1 diabetes in compar-
ison with controls. These results may be interpreted as
reflecting an exhaustion of the immune system or reflecting
a general abnormal immune reactivity during the actively
progressing T1D-associated autoimmunity.
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